Murray Caroline A, Willcox Jennifer L, De Mello Souza Carlos H, Husbands Brian, Cook Matthew R, Clifford Craig, Leeper Haley, Pellin MacKenzie, Richardson Danielle, Herrera Chamisa L, Krick Erika, McMillan Sarah, Al-Nadaf Sami, Skorupski Katherine A
William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, California, USA.
Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, California, USA.
Vet Comp Oncol. 2022 Jun;20(2):458-464. doi: 10.1111/vco.12791. Epub 2021 Dec 19.
Primary pulmonary histiocytic sarcoma (PHS) is a rare form of dendritic cell or macrophage neoplasia originating within the pulmonary parenchyma. There is limited literature describing prognosis in dogs with PHS receiving curative-intent treatment consisting of surgical excision and adjuvant chemotherapy. The primary objective of this study was to report outcomes in dogs with localized PHS treated with standardized local and systemic therapy. A secondary objective was to identify prognostic factors in this population. A multi-institutional retrospective study was performed and medical records including all surgical and histopathologic reports were retrospectively reviewed. For inclusion, dogs were required to have confirmed localized PHS and they must have undergone curative-intent surgery with resection of all gross primary tumour and enlarged tracheobronchial lymph nodes; additionally, they must have received curative-intent treatment with adjuvant single-agent CCNU chemotherapy. Twenty-seven dogs from six veterinary teaching hospitals and five private practices treated from 2008-2019 were included. The overall median survival time was 432 days. Higher CCNU dose was demonstrated to have a negative impact on survival on univariate, but not multivariable, analysis. Factors that were not found to be associated with survival on univariate analysis included body weight, breed, clinical signs at the time of diagnosis, hypoalbuminaemia, tumour size, lung lobe affected, lymph node metastasis, surgical margins and CCNU dose reductions. This study supports a favourable prognosis for dogs diagnosed with localized PHS treated with curative-intent surgery in addition to adjuvant CCNU chemotherapy and suggests that multimodal treatment may be advisable to attempt to prolong survival.
原发性肺组织细胞肉瘤（PHS）是一种起源于肺实质的罕见树突状细胞或巨噬细胞肿瘤。关于接受包括手术切除和辅助化疗在内的根治性治疗的患PHS犬的预后情况，相关文献有限。本研究的主要目的是报告接受标准化局部和全身治疗的局限性PHS犬的治疗结果。次要目的是确定该群体的预后因素。进行了一项多机构回顾性研究，并对包括所有手术和组织病理学报告在内的医疗记录进行了回顾性审查。纳入标准为犬确诊为局限性PHS，且必须接受了根治性手术，切除了所有肉眼可见的原发性肿瘤和肿大的气管支气管淋巴结；此外，它们必须接受了辅助单药洛莫司汀化疗的根治性治疗。纳入了2008年至2019年期间来自六家兽医教学医院和五家私人诊所治疗的27只犬。总体中位生存时间为432天。单因素分析显示，较高的洛莫司汀剂量对生存有负面影响，但多因素分析未显示此影响。单因素分析中未发现与生存相关的因素包括体重、品种、诊断时的临床症状、低白蛋白血症、肿瘤大小、受影响的肺叶、淋巴结转移、手术切缘和洛莫司汀剂量减少。本研究支持对确诊为局限性PHS并接受根治性手术加辅助洛莫司汀化疗的犬有良好的预后，并表明多模式治疗可能有助于延长生存期。
